Drug details

Lucentis (ranibizumab injection)

type of Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors

Lucentis (ranibizumab) Injection is a monoclonal antibody that works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels used to treat the wet form of age-related macular degeneration.

This drug may have the following side effects:

• blurred vision,
• sore throat,
• cough, or
• dry eyes,
• sinus pain,
• itchy or watery eyes,
• discomfort and increased tears in the affected eye(s),
• swelling of the eyelids,
• joint pain.

The following drugs are related to Lucentis, either as a replacement or used together:

• Eylea HD (aflibercept injection)
• Beovu (brolucizumab-dbll for intravitreal injection)
• Byooviz (ranibizumab-nuna injection, for intravitreal use)
• Cimerli (ranibizumab-eqrn injection)
• Vabysmo (faricimab-svoa injection)
• Macugen (pegaptanib sodium)
• Syfovre (pegcetacoplan injection, for intravitreal use)
• Susvimo (ranibizumab injection)
• Xipere (triamcinolone acetonide injectable suspension)
• Visudyne (verteporfin injection)

The following supplements are related to Lucentis, and may be used together with the drug:

• Zinc (s.)
• Beta-Carotene (s.)
• Vitamin E (s.)
• Lutein (s.)